Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Conclusion GLP-1RAs show significant promise as a potential disease-modifying therapy for neurodegenerative and inflammatory eye diseases, acting through both systemic metabolic improvements and direct ocular mechanisms, representing a paradigm shift beyond their metabolic indications
Discerning the trajectory of BBB breakdown between AD and neuroinflammation necessitates further study of the regional changes that occur, aided by improving imaging methodologies
March 4: Eyenovia and development partner Formosa Pharmaceuticals secured entry into a $1.3 billion annual market with the FDA approval of their clobetasol propionate 0.05% eye drops for post-operative inflammation and pain after eye surgery
W., Murphy, K
Cognitive functions in low-grade gliomas: disease and treatment effects
US$ 21.46
US$ 29.93
US$ 23.12
US$ 28.89
US$ 28.43
